Pancreatic Cancer Research

ResearcherUniversity Hospitals of Leicester NHS TrustNo recent work listed

Ashley Robert Dennison

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0090-503X; OpenAlex author ID A5040899091. Sources: ClinicalTrials.gov.

Their work

Papers
18 (first author 2, last author 8)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
26
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: none · 2023: 1 paper

Papers 18

  1. PET-CT in the staging of potentially resectable pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3079385/v1↗
  2. Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabin… Co-author DOI 10.1002/jpen.1952↗
  3. Significance of indeterminate pulmonary nodules in resectable pancreatic adenocarcinoma-a review. First author DOI 10.1007/s00423-020-02049-w↗
  4. Comment on "Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position". First author DOI 10.1038/s41416-020-01132-9↗
  5. Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intrave… Last author DOI 10.21037/atm.2020.02.02↗
  6. Endothelial Progenitor Cells are Increased in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine and Intravenous Omega 3 Compared with Controls Last author DOI 10.21203/rs.3.rs-36878/v1↗
  7. Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance. Co-author PMID 32051746↗
  8. ZEB1 and IL-6/11-STAT3 signalling cooperate to define invasive potential of pancreatic cancer cells via differential regulation of the expression of S100 prote… Co-author DOI 10.1038/s41416-019-0483-9↗
  9. Treatment Access and Survival Amongst British Asians with Pancreatic Cancer. Co-author DOI 10.1007/s00268-016-3707-7↗
  10. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.20250↗
  11. Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™. Last author DOI 10.1002/mnfr.201500755↗
  12. Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Last author DOI 10.1016/j.clnu.2013.09.017↗
  13. Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitab… Last author DOI 10.1177/0148607113476304↗
  14. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Co-author DOI 10.1007/s10620-013-2778-7↗
  15. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Last author DOI 10.1097/coc.0b013e3182124216↗
  16. Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with g… Last author DOI 10.1111/hpb.12002↗
  17. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1007/s00268-011-0984-z↗
  18. Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. Last author DOI 10.1017/s0007114511003060↗

Trials 1

  1. A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer Principal investigator NCT01019382↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Isherwood · 8 shared papers, 2014–2023 · strength 0.80
  2. Ali Raza Arshad · 9 shared papers, 2011–2021 · strength 0.74
  3. Giuseppe Garcea · 5 shared papers, 2011–2023 · strength 0.63
  4. Matthew S. Metcalfe · 10 shared papers, 1 shared trial, 2009–2020 · strength 0.62
  5. Wen Yuan Chung · 6 shared papers, 2013–2020 · strength 0.47
  6. William P. Steward · 6 shared papers, 1 shared trial, 2009–2020 · strength 0.43
  7. Franscois Runau · 3 shared papers, 2020–2021 · strength 0.35
  8. Li Lian Kuan · 1 shared paper, 2021 · strength 0.22
  9. Neil Bhardwaj · 1 shared paper, 2023 · strength 0.20
  10. Tareq Alsaoudi · 1 shared paper, 2023 · strength 0.20
  11. John M. Primrose · 1 shared paper, 2021 · strength 0.17
  12. Mark Taylor · 1 shared paper, 2021 · strength 0.17
  13. Donald J. L. Jones · 1 shared paper, 2021 · strength 0.15
  14. Yu‐Ting Chang · 1 shared paper, 2020 · strength 0.13
  15. Sén Takeda · 1 shared paper, 2020 · strength 0.13
  16. Ming‐Chu Chang · 1 shared paper, 2020 · strength 0.13
  17. Jonathan Haqq · 1 shared paper, 2016 · strength 0.08
  18. Qais Al Ismaeel · 1 shared paper, 2019 · strength 0.08
  19. Marina V. Kriajevska · 1 shared paper, 2019 · strength 0.08
  20. Margaret M. Manson · 1 shared paper, 2017 · strength 0.06
  21. Patricia Adamo · 1 shared paper, 2017 · strength 0.06
  22. Jacqui Shaw · 1 shared paper, 2017 · strength 0.06
  23. Andrew R. Hart · 1 shared paper, 2013 · strength 0.03
  24. Frank J. Carey · 1 shared paper, 2013 · strength 0.03
  25. Allan Clark · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.